Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1

Author(s): Chen D, Irving B, Hodi F


Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase have been described in a variety of human malignancies including non–small-cell lung cancer (NSCLC), cholangiocarcinoma and glioblastoma multiforme. Recently, clinicopathologic characteristics of c-ros oncogene 1, receptor tyrosine kinase (ROS1)-rearranged NSCLC patients have been described. Furthermore, anaplastic lymphoma kinase inhibitor, novel class of drugs targeting this tyrosine kinase receptor is currently under clinical trial in this molecular subset of NSCLC patients. This review will focus on the current knowledge of ROS1 rearrangements in NSCLC, methods to detect ROS1 rearrangement, and targeting ROS1-rearranged NSCLC patients with anaplastic lymphoma kinase inhibitors.

Similar Articles

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Author(s): Brahmer J, Tykodi S, Chow L, Hwu WJ, Topalian SL, et al.

Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer

Author(s): Brahmer J, Reckamp KL, Baas P, Crinò L, Wilfried EE, et al.

Immunotherapy in the treatment of non-small cell lung cancer

Author(s): Sundar R, Soong R, Cho B, Brahmer J, Soo R

When progressive disease does not mean treatment failure: Reconsidering the criteria for progression

Author(s): Oxnard G, Morris M, Hodi F, Baker LH, Kris MG, et al.